PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2020.543202153177-86Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced PneumonitisJongheon Jung, Hyae Young Kim, Dong-Gil Kim, Seog Yun Park, A Ra Ko, Ji-Youn Han, Heung Tae Kim, Jin Soo Lee, Youngjoo Leehttp://e-crt.org/upload/pdf/crt-2020-543.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2020.543, http://e-crt.org/upload/pdf/crt-2020-543.pdf
Emerging Topics in Life Sciences10.1042/etls202100642021The future of immune checkpoint combinations with tumor-targeted small molecule drugsJaclyn Sceneay, Charles Sinclairhttp://portlandpress.com/emergtoplifesci/article-pdf/doi/10.1042/ETLS20210064/915784/etls-2021-0064c.pdf, http://portlandpress.com/emergtoplifesci/article-pdf/doi/10.1042/ETLS20210064/915784/etls-2021-0064c.pdf
Reactions Weekly10.1007/s40278-020-86761-9202018321228-228Nivolumab/pembrolizumabhttp://link.springer.com/content/pdf/10.1007/s40278-020-86761-9.pdf, http://link.springer.com/article/10.1007/s40278-020-86761-9/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-020-86761-9.pdf
Journal for ImmunoTherapy of Cancer10.1136/jitc-2020-000840corr1202082e000840corr1Correction: Chronic immune checkpoint inhibitor pneumonitishttps://syndication.highwire.org/content/doi/10.1136/jitc-2020-000840corr1
Respiratory Investigation10.1016/j.resinv.2020.05.0082020585305-319Clinical burden of immune checkpoint inhibitor-induced pneumonitisKoji Sakamoto, Jun Fukihara, Masahiro Morise, Naozumi Hashimotohttps://api.elsevier.com/content/article/PII:S2212534520300939?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2212534520300939?httpAccept=text/plain
Thoracic Cancer10.1111/1759-7714.13187201910102006-2012High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancerMari Tone, Takehiro Izumo, Nobuyasu Awano, Naoyuki Kuse, Minoru Inomata, Tatsunori Jo, Hanako Yoshimura, Jonsu Minami, Kohei Takada, Shingo Miyamoto, Hideo Kunitohhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2F1759-7714.13187, https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13187, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1759-7714.13187, https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13187
Clinical Genitourinary Cancer10.1016/j.clgc.2017.07.0162017156e1073-e1080Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate CancerNobuaki Matsubara, Yoko Yamada, Ken-ichi Tabata, Takefumi Satoh, Naoto Kamiya, Hiroyoshi Suzuki, Takashi Kawahara, Hiroji Uemura, Akihiro Yano, Satoru Kawakami, Masafumi Otsuka, Satoshi Fukasawahttps://api.elsevier.com/content/article/PII:S1558767317302136?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1558767317302136?httpAccept=text/plain
Frontiers in Immunology10.3389/fimmu.2021.663986202112Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and ManagementQin Zhang, Liansha Tang, Yuwen Zhou, Wenbo He, Weimin Lihttps://www.frontiersin.org/articles/10.3389/fimmu.2021.663986/full
Respiration10.1159/00050994120209911932-942Immune Checkpoint Inhibitor-Related PneumonitisGeorgia Gomatou, Vasilios Tzilas, Elias Kotteas, Konstantinos Syrigos, Demosthenes Bouroshttps://www.karger.com/Article/Pdf/509941, https://www.karger.com/Article/Pdf/509941
Journal for ImmunoTherapy of Cancer10.1136/jitc-2020-002252202192e002252Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitisMargaret Gatti-Mays, James L Gulleyhttps://syndication.highwire.org/content/doi/10.1136/jitc-2020-002252